![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: WDR92 |
Gene summary for WDR92 |
![]() |
Gene information | Species | Human | Gene symbol | WDR92 | Gene ID | 116143 |
Gene name | dynein axonemal assembly factor 10 | |
Gene Alias | WDR92 | |
Cytomap | 2p14 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q96MX6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
116143 | WDR92 | HCC1_Meng | Human | Liver | HCC | 2.74e-25 | 3.79e-02 | 0.0246 |
116143 | WDR92 | HCC1 | Human | Liver | HCC | 1.17e-19 | 2.23e+00 | 0.5336 |
116143 | WDR92 | HCC2 | Human | Liver | HCC | 1.69e-26 | 2.95e+00 | 0.5341 |
116143 | WDR92 | HCC5 | Human | Liver | HCC | 1.11e-27 | 1.86e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR92 | SNV | Missense_Mutation | c.1006C>A | p.Leu336Ile | p.L336I | Q96MX6 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
WDR92 | SNV | Missense_Mutation | novel | c.891N>T | p.Lys297Asn | p.K297N | Q96MX6 | protein_coding | tolerated(0.45) | benign(0.075) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
WDR92 | SNV | Missense_Mutation | novel | c.752N>T | p.Ala251Val | p.A251V | Q96MX6 | protein_coding | deleterious(0.01) | benign(0.094) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
WDR92 | SNV | Missense_Mutation | c.455C>T | p.Pro152Leu | p.P152L | Q96MX6 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
WDR92 | SNV | Missense_Mutation | c.914N>G | p.Met305Arg | p.M305R | Q96MX6 | protein_coding | tolerated(0.45) | benign(0) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
WDR92 | SNV | Missense_Mutation | novel | c.627A>T | p.Lys209Asn | p.K209N | Q96MX6 | protein_coding | tolerated(0.12) | possibly_damaging(0.5) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
WDR92 | SNV | Missense_Mutation | rs747902677 | c.953N>T | p.Thr318Met | p.T318M | Q96MX6 | protein_coding | deleterious(0.02) | benign(0.164) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR92 | SNV | Missense_Mutation | novel | c.550N>C | p.Cys184Arg | p.C184R | Q96MX6 | protein_coding | deleterious(0.02) | possibly_damaging(0.637) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR92 | SNV | Missense_Mutation | rs772871130 | c.922G>A | p.Ala308Thr | p.A308T | Q96MX6 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
WDR92 | SNV | Missense_Mutation | novel | c.865T>C | p.Tyr289His | p.Y289H | Q96MX6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |